Stuti Girish Shroff, M.B.,B.S., Ph.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Fever | 2 | 2024 | 1618 | 1.010 |
Why?
|
Puerperal Disorders | 1 | 2022 | 300 | 0.680 |
Why?
|
Glomerulonephritis, IGA | 1 | 2017 | 61 | 0.570 |
Why?
|
Common Bile Duct Neoplasms | 2 | 2014 | 120 | 0.530 |
Why?
|
Ampulla of Vater | 2 | 2014 | 149 | 0.530 |
Why?
|
Abdominal Pain | 1 | 2022 | 1070 | 0.530 |
Why?
|
Dyspnea | 1 | 2023 | 1347 | 0.500 |
Why?
|
Intestinal Neoplasms | 1 | 2017 | 314 | 0.490 |
Why?
|
Carcinoma, Pancreatic Ductal | 4 | 2024 | 1727 | 0.470 |
Why?
|
Sarcoma, Kaposi | 1 | 2017 | 374 | 0.470 |
Why?
|
SOX9 Transcription Factor | 1 | 2013 | 145 | 0.420 |
Why?
|
Barrett Esophagus | 3 | 2023 | 492 | 0.410 |
Why?
|
Adenocarcinoma, Mucinous | 3 | 2024 | 517 | 0.400 |
Why?
|
Immunocompromised Host | 1 | 2017 | 858 | 0.400 |
Why?
|
Adenocarcinoma | 8 | 2022 | 6345 | 0.390 |
Why?
|
Pancreatic Ducts | 1 | 2013 | 329 | 0.380 |
Why?
|
Esophageal Neoplasms | 4 | 2023 | 1657 | 0.340 |
Why?
|
Pancreatic Neoplasms | 4 | 2024 | 5369 | 0.300 |
Why?
|
PTEN Phosphohydrolase | 1 | 2013 | 1113 | 0.290 |
Why?
|
Arteries | 4 | 1997 | 1120 | 0.290 |
Why?
|
Colonic Neoplasms | 3 | 2022 | 2533 | 0.260 |
Why?
|
Neuroendocrine Tumors | 3 | 2018 | 641 | 0.260 |
Why?
|
Melanoma | 1 | 2024 | 5696 | 0.250 |
Why?
|
Crohn Disease | 1 | 2017 | 2279 | 0.240 |
Why?
|
Cell Lineage | 1 | 2013 | 2553 | 0.230 |
Why?
|
Stomach Neoplasms | 4 | 2020 | 1459 | 0.220 |
Why?
|
Models, Cardiovascular | 4 | 1997 | 981 | 0.210 |
Why?
|
Polyendocrinopathies, Autoimmune | 1 | 2022 | 56 | 0.200 |
Why?
|
Choristoma | 1 | 2023 | 205 | 0.190 |
Why?
|
Ventricular Function, Left | 4 | 1999 | 3873 | 0.190 |
Why?
|
Nerve Tissue | 1 | 2021 | 78 | 0.180 |
Why?
|
Carcinoma | 2 | 2022 | 2328 | 0.180 |
Why?
|
Glutamine | 1 | 2023 | 576 | 0.180 |
Why?
|
Carotid Body Tumor | 1 | 2020 | 34 | 0.170 |
Why?
|
Bile Acids and Salts | 1 | 2022 | 393 | 0.170 |
Why?
|
Radiation-Sensitizing Agents | 1 | 2021 | 349 | 0.170 |
Why?
|
Neck Dissection | 1 | 2020 | 201 | 0.160 |
Why?
|
Albumins | 1 | 2021 | 575 | 0.160 |
Why?
|
Paraganglioma | 1 | 2020 | 142 | 0.160 |
Why?
|
Gastritis, Atrophic | 1 | 2018 | 32 | 0.150 |
Why?
|
p38 Mitogen-Activated Protein Kinases | 1 | 2021 | 682 | 0.150 |
Why?
|
Cysts | 1 | 2023 | 680 | 0.150 |
Why?
|
Neoplasms, Multiple Primary | 2 | 2020 | 592 | 0.150 |
Why?
|
Colonic Polyps | 1 | 2022 | 553 | 0.140 |
Why?
|
Extracellular Space | 1 | 1999 | 562 | 0.140 |
Why?
|
Acidosis | 1 | 1999 | 268 | 0.140 |
Why?
|
Lithotripsy, Laser | 1 | 1996 | 44 | 0.140 |
Why?
|
Laryngeal Neoplasms | 1 | 2020 | 514 | 0.130 |
Why?
|
Pancreas | 1 | 2023 | 1691 | 0.130 |
Why?
|
Diagnosis, Differential | 4 | 2023 | 12966 | 0.130 |
Why?
|
Inhibins | 1 | 2017 | 210 | 0.130 |
Why?
|
Cytogenetic Analysis | 1 | 2017 | 270 | 0.130 |
Why?
|
Adenomatous Polyps | 1 | 2017 | 109 | 0.130 |
Why?
|
Myocardial Contraction | 2 | 1999 | 1515 | 0.130 |
Why?
|
Postpartum Period | 1 | 2022 | 1178 | 0.130 |
Why?
|
Diarrhea | 1 | 2022 | 1317 | 0.130 |
Why?
|
Ureteral Calculi | 1 | 1996 | 114 | 0.130 |
Why?
|
Receptor, Notch1 | 1 | 2017 | 496 | 0.120 |
Why?
|
Iatrogenic Disease | 1 | 2017 | 538 | 0.120 |
Why?
|
Liver Neoplasms | 2 | 2022 | 4309 | 0.110 |
Why?
|
Paclitaxel | 1 | 2021 | 1730 | 0.110 |
Why?
|
Disease Progression | 5 | 2023 | 13495 | 0.110 |
Why?
|
Fatty Acids | 1 | 2021 | 1808 | 0.110 |
Why?
|
Pancreaticoduodenectomy | 2 | 2014 | 509 | 0.110 |
Why?
|
Prednisone | 1 | 2017 | 1562 | 0.100 |
Why?
|
Receptors, Notch | 1 | 2017 | 743 | 0.100 |
Why?
|
Colorectal Neoplasms | 2 | 2022 | 6927 | 0.100 |
Why?
|
14-alpha Demethylase Inhibitors | 1 | 2011 | 4 | 0.100 |
Why?
|
Aorta | 3 | 1997 | 2041 | 0.100 |
Why?
|
Hepatitis C | 1 | 2022 | 1580 | 0.100 |
Why?
|
Molecular Diagnostic Techniques | 1 | 2017 | 610 | 0.100 |
Why?
|
Humans | 34 | 2024 | 760740 | 0.100 |
Why?
|
Fructose-Bisphosphate Aldolase | 1 | 2011 | 48 | 0.100 |
Why?
|
Tissue Array Analysis | 1 | 2013 | 550 | 0.100 |
Why?
|
Cyclin D1 | 1 | 2014 | 451 | 0.100 |
Why?
|
Clotrimazole | 1 | 2011 | 76 | 0.100 |
Why?
|
Adenoma | 1 | 2022 | 2159 | 0.100 |
Why?
|
Cholangiocarcinoma | 1 | 2017 | 553 | 0.090 |
Why?
|
Bile Duct Neoplasms | 1 | 2017 | 606 | 0.090 |
Why?
|
Liver Cirrhosis | 1 | 2021 | 1927 | 0.090 |
Why?
|
Forkhead Transcription Factors | 3 | 2022 | 1614 | 0.090 |
Why?
|
Resuscitation | 1 | 1995 | 672 | 0.090 |
Why?
|
Rabbits | 4 | 1999 | 4770 | 0.090 |
Why?
|
Immunohistochemistry | 4 | 2021 | 11069 | 0.090 |
Why?
|
Gene Expression Profiling | 3 | 2021 | 9417 | 0.090 |
Why?
|
Carcinoma, Hepatocellular | 1 | 2022 | 2292 | 0.080 |
Why?
|
Female | 20 | 2024 | 392203 | 0.080 |
Why?
|
Male | 19 | 2024 | 360402 | 0.080 |
Why?
|
Neoadjuvant Therapy | 1 | 2020 | 2827 | 0.080 |
Why?
|
Liver Transplantation | 1 | 2020 | 2328 | 0.080 |
Why?
|
Shock, Septic | 1 | 1995 | 769 | 0.080 |
Why?
|
Carcinoma, Papillary | 1 | 2013 | 785 | 0.080 |
Why?
|
Proto-Oncogene Proteins B-raf | 3 | 2022 | 2057 | 0.080 |
Why?
|
Anti-Inflammatory Agents | 1 | 2017 | 1810 | 0.070 |
Why?
|
Gastrointestinal Stromal Tumors | 1 | 2013 | 617 | 0.070 |
Why?
|
Stroke Volume | 2 | 1999 | 5486 | 0.070 |
Why?
|
Middle Aged | 14 | 2024 | 220603 | 0.070 |
Why?
|
Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2022 | 3245 | 0.070 |
Why?
|
Cell Transformation, Neoplastic | 1 | 2017 | 2821 | 0.070 |
Why?
|
Disease-Free Survival | 2 | 2017 | 6807 | 0.070 |
Why?
|
Young Adult | 4 | 2023 | 59191 | 0.070 |
Why?
|
Blood Volume | 2 | 1999 | 547 | 0.070 |
Why?
|
Early Detection of Cancer | 1 | 2020 | 3196 | 0.070 |
Why?
|
Fluorouracil | 2 | 2021 | 1642 | 0.060 |
Why?
|
Autoimmune Diseases | 1 | 2018 | 2238 | 0.060 |
Why?
|
Prognosis | 4 | 2024 | 29601 | 0.060 |
Why?
|
Tumor Suppressor Protein p53 | 3 | 2023 | 2916 | 0.060 |
Why?
|
Adult | 12 | 2024 | 220995 | 0.060 |
Why?
|
Lung | 1 | 2023 | 9999 | 0.060 |
Why?
|
Neoplasm Invasiveness | 2 | 2024 | 3593 | 0.060 |
Why?
|
Blood Pressure | 2 | 1996 | 8473 | 0.050 |
Why?
|
Neoplasms | 2 | 2023 | 22131 | 0.050 |
Why?
|
Kaplan-Meier Estimate | 1 | 2013 | 6473 | 0.050 |
Why?
|
Retroperitoneal Space | 1 | 2023 | 170 | 0.050 |
Why?
|
Aged, 80 and over | 6 | 2024 | 58919 | 0.050 |
Why?
|
Glutamates | 1 | 2023 | 389 | 0.050 |
Why?
|
Vascular Resistance | 2 | 1995 | 930 | 0.050 |
Why?
|
Endometrial Neoplasms | 1 | 2011 | 1365 | 0.050 |
Why?
|
Agrin | 1 | 2022 | 75 | 0.050 |
Why?
|
Proline | 1 | 2023 | 455 | 0.050 |
Why?
|
Micelles | 1 | 2022 | 192 | 0.050 |
Why?
|
MutS Homolog 2 Protein | 1 | 2022 | 197 | 0.050 |
Why?
|
Genetic Predisposition to Disease | 2 | 2020 | 17878 | 0.050 |
Why?
|
Registries | 1 | 2017 | 8209 | 0.050 |
Why?
|
Neoplasm Staging | 3 | 2024 | 11118 | 0.040 |
Why?
|
Permeability | 1 | 2022 | 721 | 0.040 |
Why?
|
Coloring Agents | 1 | 2023 | 562 | 0.040 |
Why?
|
Gastric Mucosa | 1 | 2023 | 603 | 0.040 |
Why?
|
Hoarseness | 1 | 2020 | 63 | 0.040 |
Why?
|
Respiratory Mucosa | 1 | 2023 | 438 | 0.040 |
Why?
|
Aged | 9 | 2024 | 169092 | 0.040 |
Why?
|
Liver Function Tests | 1 | 2021 | 524 | 0.040 |
Why?
|
Diagnostic Imaging | 1 | 2013 | 3527 | 0.040 |
Why?
|
Compliance | 2 | 1997 | 99 | 0.040 |
Why?
|
Tumor Microenvironment | 2 | 2022 | 3868 | 0.040 |
Why?
|
DNA Mismatch Repair | 1 | 2022 | 428 | 0.040 |
Why?
|
Computational Biology | 2 | 2021 | 3509 | 0.040 |
Why?
|
Mucins | 1 | 2022 | 568 | 0.040 |
Why?
|
Biopsy | 2 | 2023 | 6763 | 0.040 |
Why?
|
Leucovorin | 1 | 2020 | 643 | 0.040 |
Why?
|
Organ Preservation | 1 | 2020 | 382 | 0.040 |
Why?
|
Metaplasia | 1 | 2018 | 324 | 0.030 |
Why?
|
Deoxycytidine | 1 | 2021 | 878 | 0.030 |
Why?
|
Vasomotor System | 1 | 1997 | 207 | 0.030 |
Why?
|
Mathematics | 1 | 1997 | 707 | 0.030 |
Why?
|
Gastroscopy | 1 | 2018 | 211 | 0.030 |
Why?
|
Lymphocytes, Tumor-Infiltrating | 1 | 2022 | 1088 | 0.030 |
Why?
|
Smad4 Protein | 1 | 2017 | 191 | 0.030 |
Why?
|
Perfusion | 1 | 2020 | 1373 | 0.030 |
Why?
|
Liver | 2 | 2022 | 7512 | 0.030 |
Why?
|
Treatment Outcome | 5 | 2021 | 64572 | 0.030 |
Why?
|
Pressure | 1 | 1999 | 1150 | 0.030 |
Why?
|
Cardiovascular Physiological Phenomena | 1 | 1997 | 241 | 0.030 |
Why?
|
Ligands | 1 | 2022 | 3268 | 0.030 |
Why?
|
Diastole | 1 | 1997 | 781 | 0.030 |
Why?
|
Nitroprusside | 1 | 1995 | 272 | 0.030 |
Why?
|
Hemodynamics | 2 | 1995 | 4160 | 0.030 |
Why?
|
Proportional Hazards Models | 2 | 2021 | 12448 | 0.030 |
Why?
|
Disease Susceptibility | 1 | 2021 | 1788 | 0.030 |
Why?
|
Animals | 7 | 2022 | 168202 | 0.030 |
Why?
|
Tumor Burden | 1 | 2020 | 1892 | 0.030 |
Why?
|
Hepatocytes | 1 | 2021 | 1231 | 0.030 |
Why?
|
Adolescent | 5 | 2023 | 88247 | 0.030 |
Why?
|
Vasodilation | 1 | 1997 | 962 | 0.030 |
Why?
|
Proto-Oncogene Proteins c-akt | 1 | 2022 | 2456 | 0.030 |
Why?
|
Retrospective Studies | 3 | 2024 | 80583 | 0.030 |
Why?
|
Elasticity | 1 | 1995 | 655 | 0.030 |
Why?
|
Esophagectomy | 1 | 2017 | 468 | 0.030 |
Why?
|
Gastrectomy | 1 | 2018 | 671 | 0.030 |
Why?
|
ROC Curve | 1 | 2021 | 3575 | 0.030 |
Why?
|
Cyclin-Dependent Kinase Inhibitor p21 | 1 | 2014 | 360 | 0.030 |
Why?
|
Endotoxins | 1 | 1995 | 520 | 0.030 |
Why?
|
Epithelial-Mesenchymal Transition | 1 | 2017 | 737 | 0.030 |
Why?
|
Stress, Mechanical | 1 | 1997 | 1674 | 0.030 |
Why?
|
Vasoconstriction | 1 | 1995 | 592 | 0.030 |
Why?
|
Fatal Outcome | 1 | 2017 | 1835 | 0.020 |
Why?
|
Biopsy, Needle | 1 | 2017 | 1624 | 0.020 |
Why?
|
Regional Blood Flow | 1 | 1995 | 1496 | 0.020 |
Why?
|
Statistics, Nonparametric | 1 | 2017 | 2851 | 0.020 |
Why?
|
Gene Expression Regulation, Neoplastic | 2 | 2021 | 8542 | 0.020 |
Why?
|
Mesoderm | 1 | 2013 | 674 | 0.020 |
Why?
|
Dogs | 1 | 1995 | 3837 | 0.020 |
Why?
|
Precancerous Conditions | 1 | 2017 | 982 | 0.020 |
Why?
|
Catheterization | 1 | 1995 | 1428 | 0.020 |
Why?
|
Terminology as Topic | 1 | 2017 | 1528 | 0.020 |
Why?
|
Stomach | 1 | 2013 | 696 | 0.020 |
Why?
|
Cell Proliferation | 1 | 2023 | 10429 | 0.020 |
Why?
|
Chronic Disease | 1 | 2022 | 9310 | 0.020 |
Why?
|
Proto-Oncogene Proteins c-bcl-2 | 1 | 2014 | 1404 | 0.020 |
Why?
|
Gene Expression Regulation, Enzymologic | 1 | 2011 | 1169 | 0.020 |
Why?
|
Academic Medical Centers | 1 | 2017 | 2756 | 0.020 |
Why?
|
Rats | 1 | 2022 | 23716 | 0.020 |
Why?
|
Head and Neck Neoplasms | 1 | 2020 | 2894 | 0.020 |
Why?
|
Follow-Up Studies | 2 | 2017 | 39062 | 0.020 |
Why?
|
Antihypertensive Agents | 1 | 1995 | 2018 | 0.020 |
Why?
|
Models, Biological | 1 | 2021 | 9461 | 0.020 |
Why?
|
Stents | 1 | 1996 | 3177 | 0.010 |
Why?
|
Magnetic Resonance Imaging | 2 | 2023 | 36401 | 0.010 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 1 | 2011 | 4569 | 0.010 |
Why?
|
Survival Analysis | 1 | 2017 | 10072 | 0.010 |
Why?
|
Gene Expression Regulation | 1 | 2021 | 11874 | 0.010 |
Why?
|
Length of Stay | 1 | 1996 | 6418 | 0.010 |
Why?
|
Disease Models, Animal | 1 | 2021 | 18220 | 0.010 |
Why?
|
Cell Survival | 1 | 2011 | 5780 | 0.010 |
Why?
|
Predictive Value of Tests | 1 | 2017 | 15250 | 0.010 |
Why?
|
Contrast Media | 1 | 2013 | 5305 | 0.010 |
Why?
|
Time Factors | 2 | 1999 | 39908 | 0.010 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 1 | 2020 | 11735 | 0.010 |
Why?
|
Cross-Sectional Studies | 1 | 2020 | 26065 | 0.010 |
Why?
|
Phenotype | 1 | 2017 | 16572 | 0.010 |
Why?
|
Polymorphism, Single Nucleotide | 1 | 2017 | 15908 | 0.010 |
Why?
|
Tomography, X-Ray Computed | 1 | 2020 | 20556 | 0.010 |
Why?
|
RNA, Messenger | 1 | 2011 | 12759 | 0.010 |
Why?
|
Pulsatile Flow | 1 | 1997 | 320 | 0.010 |
Why?
|
Risk Assessment | 1 | 2017 | 23974 | 0.010 |
Why?
|
Pregnancy | 1 | 1997 | 29869 | 0.010 |
Why?
|
Hypertension | 1 | 1995 | 8532 | 0.010 |
Why?
|
Atenolol | 1 | 1995 | 99 | 0.010 |
Why?
|
Nifedipine | 1 | 1995 | 221 | 0.010 |
Why?
|
Ramipril | 1 | 1995 | 102 | 0.010 |
Why?
|
Signal Transduction | 1 | 2017 | 23415 | 0.010 |
Why?
|
Mice | 1 | 2021 | 81368 | 0.010 |
Why?
|
Echocardiography | 2 | 1997 | 4987 | 0.010 |
Why?
|
Blood Flow Velocity | 1 | 1997 | 1369 | 0.010 |
Why?
|
Ultrasonography, Doppler | 1 | 1995 | 462 | 0.010 |
Why?
|
Risk Factors | 1 | 2018 | 74128 | 0.010 |
Why?
|
Reference Values | 1 | 1997 | 4919 | 0.010 |
Why?
|
Cross-Over Studies | 1 | 1995 | 2079 | 0.000 |
Why?
|
Administration, Oral | 1 | 1995 | 4010 | 0.000 |
Why?
|
Analysis of Variance | 1 | 1995 | 6223 | 0.000 |
Why?
|
Double-Blind Method | 1 | 1995 | 12333 | 0.000 |
Why?
|